Analysis of the relationship between immunogenicity and immunity for viral subunit vaccines

Journal of Medical Virology

Volumn 64, Issue 4, 2001, Pages 560-568

  Wilson, J N ^a   Nokes, D J ^a   Dimmock, N J ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Hepatitis B virus; Influenza A virus; PreS vaccine; Vaccine design

Indexed keywords

ANTIBODY; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; DRUG MECHANISM; IMMUNOGENICITY; INFECTION PREVENTION; NONHUMAN; RABBIT; VIRUS INFECTION; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; MODELS, IMMUNOLOGICAL; PROTEIN PRECURSORS; VACCINATION; VACCINES, SUBUNIT; VIRAL VACCINES;

HEPATITIS B VIRUS; INFLUENZA A VIRUS;

EID: 0034975048     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.1086     Document Type: Article

References (53)

1. Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects
2. Immunogenicity and protective efficacy of low dose recombinant DNA hepatitis B vaccine in normal and high-risk neonates
3. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice
4. The generation and maintenance of antibody and B cell memory
5. Selection of neutralizing antibody escape mutants with type A influenza virus HA-specific polyclonal antisera: Possible significance for antigenic drift
6. Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal)
7. Scheduling of revaccination against hepatitis B virus
8. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants
9. A pilot model of vaccination against hepatitis B virus suitable for mass vaccination campaigns in hyperendemic areas
10. Are booster immunisations needed for lifelong hepatitis B immunity?
11. The measurement and interpretation of age-specific vaccine efficacy
12. Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation
13. The prevention of hepatitis B with vaccine: Report of the centers for disease control multi-center efficacy trial among homosexual men
14. Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine)
15. Protective potential of hepatitis B virus antigens other than the S gene protein
16. Modern concepts in immune recognition and lymphocyte activation
17. Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence
18. Laboratory correlates of protection against Haemophilus influenzae type b disease: Importance of assessment of antibody avidity and immunologic memory
19. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men
20. Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: A preliminary report
21. Protection against hepatitis B virus infection by immunization with hepatitis B core antigen
22. What level of hepatitis B antibody is protective?
23. Immunogenicity of a "pre-S2 plus S" hepatitis B vaccine in healthy adults
24. Method of statistical differentials
25. Pre-S proteins in hepatitis B
26. Immunological characteristics of a recombinant hepatitis B virus-derived multiple-epitope polypeptide: A study in polyvalent vaccine design
27. All rabbits immunized with type A influenza virions have a serum haemagglutination-inhibition antibody response biased to a single epitope in antigenic site B
28. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen
29. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines
30. Long-term efficacy of plasma-derived hepatitis B vaccine: A 15-year follow-up study among Chinese children
31. Neonatal tetanus despite protective serum antitoxin concentration
32. Imperfect vaccines and herd immunity to HIV
33. DNA-mediated immunization to the hepatitis B surface antigen in mice: Aspects of the humoral response mimic hepatitis B viral infection in humans
34. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity
35. Diphtheria booster vaccination: One or two injections?
36. Half-life of HBs antibody after hepatitis B vaccination: An aid to timing of booster vaccination
37. Weak immunogenicity of the preS2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine
38. Recommendations for use of hepatitis B immune globulin (HBIG)
39. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory
40. The minimum protective level of antibodies in smallpox
41. High and low efficiency neutralization epitopes on the haemagglutinin of type A influenza virus
42. Rubella immunity. Defining the level of protective antibody
43. Prevention of mother-to-infant transmission of hepatitis B virus with use of a preS2-containing vaccine in Bali, Indonesia
44. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: Poliovirus vaccination
45. Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): Phase 1, 2 and 3 clinical testing
46. A study of the antigenicity and immunogenicity of a new hepatitis B vaccine using a panel of monoclonal antibodies
47. Vaccine induced immunologic memory for hepatitis B surface antigen: Implications for policy on booster vaccination
48. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages
49. Predictions of the emergence of vaccine-resistant hepatitis B in The Gambia using a mathematical model
50. Hepatitis B vaccine in infants from an endemic area: Long-term anti-HBs persistence and revaccination
51. Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production
52. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: Randomised double blind dose-response study